Polymyxin B

Polymyxin B is a polypeptide antibiotic derived from Bacillus polymyxa that has established itself as an important topical antimicrobial agent in veterinary medicine for treating superficial bacterial infections in cats. This medication demonstrates excellent activity against gram-negative bacteria, making it particularly valuable for infections caused by organisms such as Pseudomonas aeruginosa, Escherichia coli, and Klebsiella species. Polymyxin B is most commonly encountered in combination products with other antibiotics such as neomycin and bacitracin to provide broader spectrum coverage against both gram-positive and gram-negative pathogens. The drug is primarily used topically for ocular, otic, and skin infections where gram-negative coverage is desired.

The mechanism of action of polymyxin B involves disruption of bacterial cell membrane integrity through binding to lipopolysaccharide components of the outer membrane of gram-negative bacteria. This binding action increases membrane permeability, leading to leakage of essential cellular contents and ultimately bacterial cell death. The bactericidal effect is rapid and concentration-dependent, with bacterial killing occurring within minutes of drug exposure at therapeutic concentrations. This membrane-disrupting mechanism is unique among antibiotics and explains why polymyxin B retains activity against many bacteria that have developed resistance to other antimicrobial classes.

Polymyxin B is available in various topical formulations designed for different anatomical sites and clinical applications. Ophthalmic solutions and ointments provide treatment for bacterial eye infections, often in combination with other antibiotics and sometimes corticosteroids. Otic preparations treat external ear infections and may combine polymyxin B with antibiotics, antifungals, and anti-inflammatory agents. Topical powders and solutions are available for skin infections. The drug is rarely used systemically in cats due to significant nephrotoxicity and neurotoxicity associated with parenteral administration, but topical use carries minimal systemic risk due to poor absorption across intact epithelial surfaces.

The safety profile of polymyxin B when used topically in cats is generally excellent, as systemic absorption from ophthalmic, otic, and dermal applications is minimal. This limited absorption makes topical polymyxin B preparations suitable for cats with concurrent health conditions that might preclude systemic antibiotic use. However, veterinary supervision remains essential to ensure appropriate diagnosis, correct product selection, and proper monitoring of treatment response. Completing the full prescribed course of therapy helps ensure bacterial eradication and prevents the development of antimicrobial resistance.

Polymyxin B is primarily indicated for the topical treatment of superficial bacterial infections caused by susceptible gram-negative organisms in cats. The drug's excellent activity against Pseudomonas aeruginosa and other gram-negative pathogens makes it particularly valuable for infections where these organisms are suspected or confirmed. Most commonly, polymyxin B is used as a component of combination products that also include gram-positive coverage, providing broad-spectrum protection against the range of bacteria typically encountered in superficial infections. The topical route of administration limits the drug's utility to infections accessible to direct application.

Bacterial conjunctivitis represents one of the most common applications of polymyxin B-containing ophthalmic products in feline medicine. Eye infections in cats can result from primary bacterial invasion, secondary infection following viral disease or trauma, or complications of anatomical abnormalities. Polymyxin B provides coverage against gram-negative organisms that may cause or complicate conjunctival infections, while combination products with neomycin or bacitracin extend coverage to gram-positive bacteria such as staphylococci and streptococci. The broad-spectrum coverage makes these combinations suitable for empirical treatment before culture results are available.

External ear infections, known as otitis externa, represent another important indication for polymyxin B use in cats. Feline ear infections commonly involve mixed bacterial populations including both gram-positive and gram-negative organisms, often complicated by yeast overgrowth. Polymyxin B-containing otic preparations provide gram-negative coverage as part of combination products that may also include neomycin, hydrocortisone, and antifungal agents to address the multiple components of ear disease. The anti-inflammatory component helps reduce the pain and swelling associated with ear infections while antimicrobials address the infectious etiology.

Superficial skin infections and wound care represent additional applications where polymyxin B may be beneficial. Topical preparations can be applied to minor cuts, abrasions, and areas of superficial pyoderma where gram-negative bacteria may be present. Combination antibiotic preparations containing polymyxin B provide coverage for the mixed bacterial populations typically found in contaminated wounds. The drug may be used prophylactically following minor surgical procedures or trauma to prevent bacterial colonization of healing tissues.

The selection of polymyxin B-containing products over alternatives depends on the suspected or confirmed bacterial pathogens, the anatomical site of infection, and the specific clinical presentation. Products are chosen based on whether gram-negative coverage is needed alone or in combination with gram-positive coverage, whether anti-inflammatory action is desired, and whether antifungal activity is required. Veterinarians consider culture results when available, though empirical treatment with broad-spectrum combinations is often initiated pending laboratory confirmation. The availability of various formulations allows selection of the most appropriate product for each clinical situation.

The dosing protocol for polymyxin B in cats depends on the specific formulation, the anatomical site of application, and the nature of the infection being treated. Unlike systemic medications that are dosed by body weight, topical polymyxin B products are applied in quantities appropriate to cover the affected area or achieve adequate local drug concentrations. The veterinarian provides specific instructions for each product, including the amount to apply, frequency of administration, and duration of treatment. These instructions should be followed precisely to ensure optimal therapeutic outcomes.

Ophthalmic polymyxin B preparations are typically applied to affected eyes one to four times daily, depending on the specific product and the severity of infection. Solutions are administered as one to two drops per eye, while ointments are applied as a thin ribbon to the conjunctival surface or lower eyelid. More severe infections may require more frequent application initially, with reduction in frequency as clinical improvement occurs. The veterinarian establishes the exact regimen based on the clinical presentation and the specific product characteristics. Consistent application intervals help maintain therapeutic drug concentrations on the ocular surface.

Treatment duration for ophthalmic and other topical polymyxin B applications typically ranges from five to fourteen days depending on the type and severity of infection and clinical response. Uncomplicated bacterial conjunctivitis may resolve with shorter treatment courses, while more severe or chronic infections require extended therapy. Veterinary reassessment during the treatment course allows evaluation of response and adjustment of duration as needed. Treatment should continue for at least two to three days after clinical resolution to ensure complete bacterial eradication. Extended treatment beyond two weeks should only occur under continued veterinary supervision.

Otic preparations containing polymyxin B require proper ear cleaning before application to remove debris and discharge that could impair drug penetration. The veterinarian may perform initial ear cleaning and demonstrate proper technique for home care. The prescribed number of drops is instilled into the ear canal, followed by gentle massage of the ear base to distribute medication throughout the canal. Treatment frequency is typically two to three times daily, though the specific product label and veterinary instructions should be followed. Ear infections often require more extended treatment than eye infections due to the anatomy and chronic nature of many otic conditions.

Proper administration technique significantly impacts treatment success with all polymyxin B formulations. For eye drops, the cat should be gently restrained, the head tilted upward, and drops applied without touching the dropper tip to the eye surface. For ointments, the lower eyelid is pulled down to create a pocket for medication placement. Otic applications require the ear pinna to be lifted to straighten the ear canal for drop instillation. Hands should be washed before and after medication administration. If multiple topical eye products are prescribed, the veterinarian provides guidance on the order and timing of application.

Completing the full prescribed course of polymyxin B therapy is important even when clinical signs appear to resolve before treatment is finished. Premature discontinuation may allow surviving bacteria to repopulate and potentially develop resistance, leading to recurrent or resistant infections. Bacterial populations below clinically detectable levels can persist and cause relapse if treatment is stopped too early. Cat owners should contact their veterinarian before discontinuing treatment early, as there may be clinical reasons to modify the treatment plan based on response.

Polymyxin B demonstrates an excellent safety profile when used topically in cats, with most patients completing treatment without experiencing significant adverse effects. The minimal systemic absorption associated with ophthalmic, otic, and dermal application means that the nephrotoxicity and neurotoxicity associated with parenteral polymyxin B are not concerns with topical use. However, local reactions at the site of application can occur in some cats, and owners should maintain awareness of potential adverse effects throughout treatment. Understanding possible side effects enables prompt recognition and appropriate response.

The most commonly observed side effects with topical polymyxin B in cats involve local irritation at the application site. Ophthalmic products may cause transient stinging, burning, or discomfort immediately following application, evidenced by increased blinking, squinting, or brief pawing at the eye. These reactions are typically mild and resolve within minutes. Some cats may show mild redness or increased tear production immediately following eye drop administration. Otic preparations may cause head shaking or ear scratching following application, particularly if the ear canal is inflamed or if the medication causes mild stinging.

Moderate side effects are uncommon but may include persistent local irritation, allergic contact dermatitis, or apparent worsening of symptoms despite treatment. Prolonged use of some polymyxin B combinations, particularly those containing neomycin, may lead to sensitization and allergic reactions in susceptible individuals. Signs of allergic reaction include increased redness, swelling, and itching at the application site. If the treated condition appears to worsen or if new symptoms develop during treatment, veterinary reassessment is indicated to determine whether a medication reaction is occurring or whether the diagnosis needs reconsideration.

Serious adverse effects from topical polymyxin B are rare when the drug is used as directed but could theoretically include systemic allergic reactions or toxicity if massive amounts were applied to large areas of damaged tissue allowing significant absorption. Signs of systemic allergic reaction may include facial swelling, hives, difficulty breathing, or collapse, requiring emergency veterinary attention. Application to the eye of products not formulated for ophthalmic use could cause severe corneal damage. Using otic preparations in ears with ruptured tympanic membranes could potentially result in ototoxicity or vestibular effects if drug reaches the middle or inner ear.

Rare side effects specific to combination products may include reactions to other components such as neomycin-induced contact sensitivity or corticosteroid-related effects if products containing anti-inflammatory agents are used. Prolonged topical antibiotic use can theoretically promote emergence of resistant organisms or fungal overgrowth. Cat owners should contact their veterinarian if significant local irritation develops, if the condition worsens despite treatment, if signs of allergic reaction occur, or if there is no improvement within the expected timeframe. Prompt communication enables appropriate treatment modification when adverse effects occur.

Polymyxin B is contraindicated in cats with known hypersensitivity or allergy to polymyxin B or other polypeptide antibiotics. Previous allergic reactions to polymyxin B-containing products indicate that alternative treatments should be selected to avoid potentially serious allergic responses. Cats sensitized to neomycin, which is commonly combined with polymyxin B in many products, should not receive neomycin-polymyxin combinations, though single-agent polymyxin B may still be appropriate if available. Complete medication history, including any previous reactions to topical products, helps ensure safe prescribing decisions.

Otic preparations containing polymyxin B should not be used in ears with known or suspected tympanic membrane perforation, as drug reaching the middle and inner ear can cause ototoxicity and vestibular effects. The veterinarian should examine the ear canal and tympanic membrane before prescribing otic polymyxin B products. If the ear drum cannot be visualized due to discharge or swelling, or if perforation is suspected based on clinical signs, systemic antibiotics may be more appropriate than topical treatment. Cats with a history of ear surgery affecting the tympanic membrane require careful evaluation before otic antibiotic use.

Ophthalmic polymyxin B products have few specific contraindications beyond hypersensitivity, but certain eye conditions may require careful consideration. Deep corneal ulcers or penetrating eye injuries may require different treatment approaches, and the veterinarian evaluates the specific ocular condition before prescribing. Viral eye infections such as feline herpesvirus keratitis are not appropriate for polymyxin B treatment as the drug has no antiviral activity, though secondary bacterial infection may warrant antibiotic use. Products containing corticosteroids should be used cautiously in eyes with ulcers due to potential interference with healing.

Pregnancy and lactation do not represent absolute contraindications to topical polymyxin B use due to minimal systemic absorption from properly applied topical products. However, veterinarians may consider the reproductive status when making treatment decisions. Kittens can generally receive topical polymyxin B products when indicated, with appropriate veterinary assessment of the condition and product selection. Other relative contraindications are primarily related to specific combination products rather than polymyxin B itself, and the veterinarian considers all product components when determining appropriateness for individual patients.

Providing the veterinarian with a complete list of all medications and topical products the cat currently receives is important before initiating polymyxin B therapy, as interactions can affect treatment efficacy or safety. While systemic drug interactions with topical polymyxin B are highly unlikely due to minimal absorption, local interactions with other topical products applied to the same site can occur. Understanding potential interactions enables optimal treatment planning and appropriate management of combination therapy.

When multiple ophthalmic medications are prescribed simultaneously, proper coordination of administration timing maximizes the effectiveness of each product. Applying multiple eye drops too close together can result in one medication washing out another before adequate absorption occurs. Veterinarians typically recommend waiting at least five to ten minutes between different eye drop applications, with ointments applied last due to their longer retention time and potential to impair absorption of subsequent drops. The order of medication application may be specified based on product characteristics and therapeutic goals.

Otic preparations containing polymyxin B may interact with other ear medications, cleaning solutions, or concurrent treatments for ear disease. The veterinarian coordinates timing of ear cleaning, medication application, and any other treatments to optimize efficacy. Some ear cleaning solutions may inactivate certain antibiotics, so the interval between cleaning and medication application is important. If multiple otic products are prescribed, specific instructions regarding order and timing of application should be followed carefully.

Monitoring for interactions involves assessing treatment response and watching for unexpected effects. Failure of expected improvement may indicate an interaction affecting drug efficacy, inappropriate product selection, or misdiagnosis of the underlying condition. Increased local irritation when using multiple products may represent additive irritant effects or sensitivity to one of the components. Regular veterinary follow-up allows assessment of progress and identification of potential interaction effects. Cat owners should report any concerns about treatment response or suspected interactions promptly to enable appropriate management.

General precautions for polymyxin B use in cats include ensuring accurate diagnosis before initiating treatment, as the medication is only effective against susceptible bacterial infections and will not address viral, fungal, or parasitic causes of the presenting condition. Veterinary examination is essential to confirm the diagnosis and determine whether polymyxin B-containing products are appropriate. For eye and ear conditions in particular, other causes of similar symptoms must be ruled out before antibiotic therapy. Cat owners should follow all application instructions precisely and complete the full prescribed treatment course.

Product selection requires attention to the specific polymyxin B formulation and combination product prescribed, as different preparations are designed for different anatomical sites and clinical situations. Ophthalmic products should only be used in the eyes, otic products only in the ears, and topical skin products only on the skin. Using products in sites other than those intended can cause serious adverse effects, such as corneal damage from non-ophthalmic preparations applied to the eye. If products appear similar and confusion is possible, clear labeling and careful reading of product labels before each application helps prevent errors.

Environmental precautions include maintaining product sterility to prevent contamination that could introduce additional organisms to already infected tissues. Ophthalmic product applicator tips should never touch the eye surface or any other surface. Otic dropper tips should not contact the ear or surrounding skin. After each use, containers should be closed tightly. Multi-dose products have limited use periods after opening and should be discarded according to label instructions. In multi-pet households, separate medication containers should be used for each affected animal.

Monitoring during treatment includes watching for signs of improvement in the treated condition as well as any adverse effects from the medication. For eye infections, improvement should include decreased discharge, reduced redness, and improved comfort within a few days of initiating treatment. For ear infections, reduction in head shaking, discharge, and pain indicates positive response, though ear infections often improve more slowly than eye infections. Signs of toxicity or allergic reaction such as increased swelling, severe irritation, or respiratory distress require immediate veterinary attention.

Special populations requiring additional consideration include cats with compromised immune systems who may require more aggressive treatment than topical antibiotics alone can provide. Cats with underlying conditions affecting the eyes or ears may need investigation and management of predisposing factors alongside antibiotic treatment. Geriatric cats should be monitored for any signs of systemic effects, though these are unlikely with topical use. Kittens can generally receive appropriate topical polymyxin B products under veterinary supervision.

Proper storage of polymyxin B-containing products maintains medication sterility, stability, and effectiveness throughout the treatment period. Most ophthalmic and otic products should be stored at controlled room temperature between 59 and 77 degrees Fahrenheit, protected from light and excessive heat. Some products may require refrigeration, and label instructions should be followed precisely. The medication should be kept in its original container with caps tightly closed when not in use. Storage location should be away from direct sunlight, moisture, and temperature extremes that could affect product stability.

Ophthalmic and otic products require particular attention to sterility and contamination prevention. The applicator tip should never touch any surface, including the eye, ear, or surrounding tissues. If contamination occurs, the product should be discarded. Multi-dose containers have limited use periods after opening, typically four weeks for ophthalmic products, after which they should be discarded even if medication remains. Single-use packaging eliminates concerns about contamination between uses. Products should be inspected before each use for changes in appearance, color, or clarity that might indicate degradation or contamination.

Safe handling and disposal of polymyxin B products protects household members and the environment. Medications should be stored out of reach of children and other pets to prevent accidental ingestion or misuse. While topical polymyxin B has low systemic toxicity, accidental eye contact in humans should be managed by rinsing with water. Proper disposal of unused or expired medication should utilize pharmacy or veterinary clinic take-back programs when available. If take-back programs are not accessible, FDA guidelines for household medication disposal should be followed. Products should not be flushed down drains or toilets to prevent environmental contamination.

Polymyxin B can be used safely in cats of all breeds when appropriately prescribed and applied under veterinary supervision for indicated conditions. No breed-specific contraindications, toxicities, or dosing adjustments have been documented for topical polymyxin B use in feline patients. The topical nature of the medication means that breed-related variations in systemic drug metabolism are not relevant. However, awareness of breed-related anatomical characteristics and disease predispositions can help optimize treatment approaches and set appropriate expectations for response.

Certain breeds have anatomical or physiological characteristics that may influence treatment with ophthalmic or otic polymyxin B preparations. Brachycephalic breeds such as Persians, Himalayans, and Exotic Shorthairs have prominent eyes, shallow orbits, and facial conformations that may predispose them to certain eye conditions and affect tear film distribution. These breeds may require more careful monitoring during ophthalmic treatment. Scottish Folds have ear cartilage abnormalities that can predispose to otic conditions and may affect ear medication administration. Breeds with narrower ear canals may require attention to ensure adequate medication delivery.

Size differences among cat breeds have minimal impact on topical polymyxin B treatment, as the medication is applied based on the area to be treated rather than body weight. Application technique remains consistent regardless of cat size. Very small cats or kittens may have smaller anatomical structures requiring adjusted application technique for eyes and ears. Large breed cats follow the same treatment principles as smaller cats.

Age-related considerations apply across all breeds and may influence treatment decisions. Kittens have developing ocular and auditory structures that may respond differently to medications or underlying conditions. Pediatric patients may require modified restraint techniques for medication application. Geriatric cats commonly have concurrent conditions that may affect their response to treatment or predispose them to infections. Senior cats should be monitored appropriately during any treatment course. Age-appropriate veterinary evaluation and monitoring ensures optimal treatment outcomes regardless of breed background.

Polymyxin B belongs to the polypeptide antibiotic class along with the related compounds colistin (polymyxin E) and bacitracin. While polymyxin B and colistin share similar gram-negative coverage and membrane-disrupting mechanisms, colistin is used primarily for systemic applications in human medicine and has limited veterinary topical use. Bacitracin provides gram-positive coverage and is frequently combined with polymyxin B in topical preparations to create broad-spectrum products. Understanding related medications and alternatives helps inform treatment decisions when polymyxin B products are contraindicated, unavailable, or ineffective.

Alternative antibiotic options for conditions commonly treated with polymyxin B include other topical antibiotics with appropriate spectrum of activity. Gentamicin and tobramycin provide gram-negative coverage for ophthalmic and otic use. Fluoroquinolone eye drops such as ciprofloxacin offer broad-spectrum coverage. Fusidic acid provides excellent gram-positive, particularly staphylococcal, coverage. The selection among alternatives depends on the suspected or confirmed pathogen, anatomical site, and patient factors. Culture and sensitivity testing may guide antibiotic selection for refractory infections.

Complementary therapies may support polymyxin B treatment or address aspects of the condition beyond bacterial infection. For eye infections, tear supplements may be beneficial, particularly in cats with dry eye or prolonged therapy. Warm compresses can help loosen ocular discharge. For ear infections, appropriate ear cleaning is essential for optimal antibiotic effectiveness. Elizabethan collars prevent self-trauma to treated eyes or ears. Management of underlying conditions such as allergies or anatomical abnormalities helps prevent recurrent infections. Nutritional support and environmental modifications promote overall health. All complementary approaches should be discussed with the veterinarian to ensure compatibility with polymyxin B therapy. Owners should never substitute alternative treatments for prescribed antibiotic therapy without veterinary guidance, as inadequate treatment can lead to persistent or worsening infections.